CHARLESTOWN, Mass. , April 13, 2023 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing genetic medicines for neuromuscular and cardiac diseases, today announced that Bo Cumbo, President and Chief Executive Officer, will present at the 22nd Annual Needham Healthcare Conference on Thursday, April 20, 2023 at 8:00 AM ET.
Mr. Cumbo will also participate in a gene therapy panel discussion on Thursday, April 20, 2023 at 11:45 AM ET.
A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A replay will be available on the Company’s website following the event. The panel discussion will be made available live only to clients of Needham.
Institutional investors interested in meeting with management during the conference may reach out to their Needham representative.
About Solid Biosciences
Solid Biosciences is a life science company focused on advancing a portfolio of neuromuscular and cardiac programs, including SGT-003, a differentiated gene transfer candidate for the treatment of Duchenne, AVB-202-TT, a gene transfer candidate for the treatment of Friedreich’s Ataxia, AVB-401 for BAG3 mediated dilated cardiomyopathy, and additional assets for the treatment of undisclosed cardiac diseases. Solid aims to be the center of excellence, bringing together those with expertise in science, technology, disease management and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
David Carey
FINN Partners
212-867-1768
This email address is being protected from spambots. You need JavaScript enabled to view it.
Solid Biosciences Media Contact:
Tim Palmer
Associate Director, Corporate Communications
607-760-4223
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.85 |
| Daily Change: | -0.46 -8.66 |
| Daily Volume: | 350,011 |
| Market Cap: | US$187.210M |
November 06, 2024 August 13, 2024 May 07, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
